Total glucosides of paeony for rheumatoid arthritis: a protocol for a systematic review by Jing Luo, Guo-Yan Yang, Di-Er Jin, Ying-Ze Zhang, Jian-Ming Wang, Wei-Ping Kong, Qing-Wen Tao

“…RCTs comparing TGP with placebo, no treatment, or disease-modifying antirheumatic drugs for patients with RA will be retrieved. …”
Get full text

Tetracyclines in Rheumatoid Arthritis: Dual Anti-Inflammatory and Immunomodulatory Roles, Effectiveness, and Safety Insights by Mislav Radić, Andrej Belančić, Hana Đogaš, Marijana Vučković, Andrea Gelemanović, Andrea Faour, Ivan Vlak, Josipa Radić

“…Clinical trials, including double-blind, placebo-controlled studies, have shown efficacy in reducing RA symptoms, particularly in early and refractory cases. …”
Get full text

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review by Andrijana Koceva, Andrijana Koceva, Katarina Mlekuš Kozamernik, Katarina Mlekuš Kozamernik, Andrej Janež, Andrej Janež, Rok Herman, Rok Herman, Simona Ferjan, Simona Ferjan, Mojca Jensterle, Mojca Jensterle

“…It was well tolerated, even after metabolic surgery.ConclusionLong-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions.…”
Get full text

Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis. by Mei Yang, Yuying Tan, Ting Yang, Dan Xu, Mei Chen, Lei Chen

“…<h4>Methods</h4>We updated a systematic review with meta-analysis and trial sequential analysis (TSA) of randomized controlled trials and prospective studies on antifibrotic drug (nintedanib or pirfenidone) vs other intervention (placebo, no intervention or conventional treatment) in non-IPF ILDs. …”
Get full text

Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index by Sarah H. Millan, Mallory L. Hacker, Maxim Turchan, Anna L. Molinari, Amanda D. Currie, David Charles

“…This finding will be tested in an upcoming FDA-approved phase III multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial evaluating DBS in early stage PD (ClinicalTrials.gov identifier NCT00282152).…”
Get full text

Effect of probiotic and prebiotics supplementation on hemoglobin levels and iron absorption among women of reproductive age and children: a systematic review and meta-analysis by Aditi Apte, Ashwini Parge, Radhika Nimkar, Anju Sinha

“…However, there is low certainty of evidence that the intervention led to improvement in fractional absorption of iron as compared to placebo or iron [8 studies, n = 335, mean increase 0.74%, 95%CI-0.11–1.38, p = 0.02]. …”
Get full text

A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty live... by Sara Mighani, Rasoul Samimi, Mohamadreza Rashidi Nooshabadi, Seyed Amir Farzam, Hossein Khadem Haghighian, Maryam Javadi

“…Methods In this clinical trial, 44 patients were selected based on including criteria and randomly received 180 mg of EA per day (n = 22) or placebo (n = 22) for 8 weeks. At the beginning and end of the study, glycemic indices, lipid profiles, liver enzymes, oxidative stress markers, and inflammatory factors were measured. …”
Get full text

GWAS of CRP response to statins further supports the role of APOE in statin response: A GIST consortium study by Emma F. Magavern, Harshal Deshmukh, Geraldine Asselin, Elizabeth Theusch, Stella Trompet, Xiaohui Li, Raymond Noordam, Y.-D. Ida Chen, Teresa E. Seeman, Kent D. Taylor, Wendy S. Post, Jean-Claude Tardif, Dirk S. Paul, Emelia J. Benjamin, Nancy L. Heard-Costa, Ramachandran S. Vasan, Jerome I. Rotter, Ronald M. Krauss, J.Wouter Jukema, Paul M. Ridker, Patricia B. Munroe, Mark J. Caulfield, Daniel I. Chasman, Marie-Pierre Dubé, Graham A. Hitman, Helen R. Warren

“…Both loci are also associated with baseline CRP levels, and neither locus achieved a significant (P < 0.05) result from the statin v. placebo interaction meta-analysis using randomized clinical trial data. …”
Get full text

Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia: The Folic Acid Clinical Trial Study by Shi Wu Wen, Josee Champagne, Ruth Rennicks White, Doug Coyle, William Fraser, Graeme Smith, Dean Fergusson, Mark C. Walker

“…Pregnant women with increased risk of developing PE presenting to a trial participating center between 80/7 and 166/7 weeks of gestation are randomized in a 1 : 1 ratio to folic acid 4.0 mg or placebo after written consent is obtained. Intent-to-treat population will be analyzed. …”
Get full text

Macrofilaricidal Activity in Wuchereria bancrofti after 2 Weeks Treatment with a Combination of Rifampicin plus Doxycycline by Alexander Yaw Debrah, Sabine Mand, Yeboah Marfo-Debrekyei, Linda Batsa, Anna Albers, Sabine Specht, Ute Klarmann, Kenneth Pfarr, Ohene Adjei, Achim Hoerauf

“…In Ghana, a pilot study was carried out with 39 LF-infected men; 12 were treated with 200 mg doxycycline/day for 4 weeks, 16 were treated with a combination of 200 mg doxycycline/day + 10 mg/kg/day rifampicin for 2 weeks, and 11 patients received placebo. Patients were monitored for Wolbachia and microfilaria loads, antigenaemia, and filarial dance sign (FDS). …”
Get full text

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis by Saixian Shi, Xiaofeng Li, Ye Chen, Jiahao Li, Yan Dai

“…Conclusion In the comparison of new hypoglycemic drug classes, GLP1RA and SGLT2i reduced MACE, cardiovascular mortality and all‐cause mortality in T2DM patients with CVD, with no significant difference in efficacy, and DPP4i was noninferior to placebo. Only GLP1RA reduced the risk of nonfatal stroke, and only SGLT2i reduced the risk of HHF.…”
Get full text

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR by Zhongxia Wang, Tao Zhang, Lizhe Sun, Ruifeng Li, Yuanyuan Wei, Xiaojuan Fan, Zuyi Yuan, Junhui Liu, Tao Chen

“…Twenty-eight patients with coronary artery disease and who underwent DES implantations were randomly assigned to pioglitazone (30 mg/d; PIO) or placebo (control; Con) treatment in addition to optimal standard therapy. …”
Get full text

Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care by Daniela Tomasoni, Julie K.K. Vishram‐Nielsen, Matteo Pagnesi, Marianna Adamo, Carlo Mario Lombardi, Finn Gustafsson, Marco Metra

“…However, in the recent Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial, omecamtiv mecarbil was safe and effective in the reduction of the primary outcome of cardiovascular death or HF event compared with placebo (hazard ratio, 0.92; 95% confidence interval, 0.86–0.99; P = 0.03) and its effects were larger in those patients with more severe left ventricular dysfunction. …”
Get full text

Acute Effects of Ketamine Infusion on Postoperative Mood Scores in Patients Undergoing Dilation and Curettage: A Randomized Double-Blind Controlled Study by Raham Hasan Mostafa, Ahmed Mohamed Khamis, Ashraf Nabil Saleh, Yehia Mamdouh Hassan Mekki, Mohamed Mohamed Kamal, Ismail Mohammed Ibrahim, Mohamed Abdulmohsen Abdulnaiem Ismaiel

“…A prospective, randomized, double-blind, parallel-group, placebo-controlled trial. The study included a total of 60 patients, ≥18 years, physical status ASA II, with up to 12-week gestation undergoing elective D&C surgery. …”
Get full text

Digital sleep phenotype and wrist actigraphy in individuals at clinical high risk for psychosis and people with schizophrenia spectrum disorders: a systematic review and meta-analy... by Andrea Cipriani, Edoardo Giuseppe Ostinelli, John Torous, Paolo Brambilla, Philip McGuire, Dominic Oliver, Rosario Aronica, Charlotte Austin

“…The risk-of-bias assessment ranged from some concerns to high risk.Conclusions Our analyses identified sleep abnormalities in CHR-P and SSD compared with placebo. However, observed heterogeneity and potential biases across studies may limit the interpretability of findings. …”
Get full text

Therapeutic Effects of BCG Vaccination on Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Yu-Chen Chang, Chien-Ju Lin, Yu-Hsuan Hsiao, Yu-Han Chang, Shu-Jung Liu, Hsin-Yin Hsu

“…The pooled meta-analysis demonstrated no significant difference in HbA1c levels (mean difference [MD], −0.12; 95% confidence interval [CI], −0.53 to 0.30; I2=56%) or fasting C-peptide levels (MD, −0.15; 95% CI, −0.35 to 0.06; I2=0%) in the BCG intervention group as compared with that in the placebo group. Conclusions. There is no robust evidence to support the use of the BCG vaccine for the treatment of T1DM although the HbA1c levels tended to improve. …”
Get full text

Exploring the association between statins use or HMG-CoA reductase inhibition and migraine: a systematic review and meta-analysis by Hamdy A. Makhlouf, Amr K. Hassan, Nereen A. Almosilhy, Ahmed S.A. Osman, Shrouk Ramadan, Moaz Elsayed Abouelmagd

“…RCTs supported the efficacy of statins in reducing migraine frequency, days, and intensity compared to placebo. Conclusions Statins, already well-established for cardiovascular benefits, emerge as a promising dual-purpose therapy for many neurological disorders. …”
Get full text

The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial by Mehrab Sayadi, Sara Javadpour Nowbandegani, Fatemeh Balaghi Inalou, Bahman Nazemzadegan, Shirzad Javidi Alsaadi, Mohammadreza Eskandari, Matin Sepehrinia

“…The study group received two capsules of 220 mg of zinc sulfate containing 50 mg of zinc, and the control group received two capsules of 220 mg of placebo ingredient per week for 12 weeks. At the start and end of the treatment period, the fasting blood glucose (FBG), glycated hemoglobin (HbA1c), zinc level, weight, waist circumference (WC), and blood pressure were measured. …”
Get full text

NeuroEPO influence on the fetal heart in a placental insufficiency model of rats by Nìnive Nùñez Lòpez, Julito Dos Santos Dos Santos, Aida María Suàrez Aguiar, María Antonia Cruz García, Claudia Joffre Frías, Carmen Inés Morales Paneque, Laura López Marín

“…That same day, seven rats were administered NeuroEPO (0.5 mg/kg/day subcutaneously for three days) and the rest received placebo. On day 20 of gestation, the fetuses were divided into four groups: a control group, a group with intrauterine growth retardation, a NeuroEPO control group, and a group with intrauterine growth retardation and NeuroEPO. …”
Get full text

Unraveling the transcriptomic effects of leucine supplementation on muscle growth and performance in basketball athletes. by Sinan Wang, Weishuai Guo, Rui Dong

“…Participants were then given a functional drink containing either leucine (50 mg/kg body weight) or a placebo for 28 days. After supplementation, the same exercise performance metrics were reassessed. …”
Get full text